Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents

New England Journal of Medicine

Volumn 356, Issue 10, 2007, Pages 1030-1039

  Kastrati, Adnan ^a   Mehilli, Julinda ^a   Pache, Jürgen ^a   Kaiser, Christoph ^b   Valgimigli, Marco ^c   Kelbæk, Henning ^d   Menichelli, Maurizio ^e   Sabaté, Manel ^f   Suttorp, Maarten J ^g   Baumgart, Dietrich ^h   Seyfarth, Melchior ^a   Pfisterer, Matthias E ^b   Schömig, Albert ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF FERRARA   (Italy)

^d Rigshospitalet   (Denmark)

^e SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g ST ANTONIUS HOSPITAL   (Netherlands)

^h Preventicum Klinik für Diagnostik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DATA ANALYSIS; DEATH; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; THROMBOSIS; TREATMENT OUTCOME;

EID: 33847766568     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa067484     Document Type: Article

References (45)

1. Assali AR, Moustapha A, Sdringola S, et al. Acute coronary syndrome may occur with in-stent restenosis and is associated with adverse outcomes (the PRESTO trial). Am J Cardiol 2006;98:729-33.
2. Schühlen H, Kastrati A, Mehilli J, et al. Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. Am Heart J 2004;147:317-22.
3. Iijima R, Mehilli J, Schomig A, Kastrati A. Clinical evidence on polymer-based sirolimus and paclitaxel eluting stents. Minerva Cardioangiol 2006;54:539-55.
4. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
5. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006;27:2784-814.
6. Camenzind E. Safety of drug-eluting stents: insights from meta analysis. (Accessed February 9, 2007, at http://www.escardio.org/knowledge/congresses/ CongressReports/hotlinesandctus/707009_Camenzind.htm.)
7. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006;119:1056-61.
8. Kaiser C, Brunner-La Rocca HP, Buser PT, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005;366:921-9. [Erratum, Lancet 2005;366:2086.]
9. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-5.
10. Chan C, Zambahari R, Kaul U, Cohen SA, Buchbinder M. Outcomes in diabetic patients with multivessel disease and long lesions: results from the DECODE STUDY. (Accessed February 9, 2007, at http://www.tctmd.com/csportal/appmanager/ tctmd/main?_nfpb=true&_pageLabel=TCTMDContent&hdCon=1382193.)
11. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005;112:2175-83.
12. Schofer J, Schlüter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
13. Pache J, Dibra A, Mehilli J, Dirschinger J, Schömig A, Kastrati A. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J 2005;26:1262-8.
14. Suttorp MJ, Laarman GJ, Rahel BM, et al. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of 2006;114:921-8.
15. Morice M-C, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
16. Vermeersch P, Agostoni P, Verheye S, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol 2006;48:2423-31.
17. Kelbaek H, Thuesen L, Helqvist S, et al. The Stenting Coronary Arteries in Non-stress/Benestent Disease (SCANDSTENT) trial. J Am Coll Cardiol 2006;47:449-55.
18. Baumgart D. A German multicenter randomized controlled open-label study of the cypher sirolimus eluting stent in the treatment of diabetic patients with de novo native coronary artery lesions. (Accessed February 9, 2007, at http://www.attendeeinteractive.com.)
19. Ardissino D, Cavallini C, Bramucci E, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004;292:2727-34.
20. Menichelli M. Randomised trial of sirolimus stent vs bare metal stent in acute myocardial infarction (SESAMI). (Accessed February 9, 2007, at http://www.europcronline.com/fo/planning/event/europcr/consult_event.php?id=491. )
21. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
22. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005;293:2109-17.
23. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006;355:1093-104.
24. Altman DG, Schulz KF. Concealing treatment allocation in randomised trials. BMJ 2001;323:446-7.
25. Jüni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
26. Egger M, Smith GD, Altman D, eds. Systematic reviews in health care: metaanalysis in context. London: BMJ Publishing, 2001:357.
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
29. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004;364:583-91.
30. Holmes DR Jr, Moses JW, Schofer J, Morice MC, Schampaert E, Leon MB. Cause of death with bare metal and sirolimus-eluting stents. Eur Heart J 2006;27:2815-22.
31. Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45:954-9.
32. Indolfi C, Pavia M, Angelillo IF. Drug-eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis). Am J Cardiol 2005;95:1146-52.
33. Biondi-Zoccai GG, Agostoni P, Abbate A, et al. Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-metal-stent-controlled trials. Int J Cardiol 2005;100:119-23.
34. Katritsis DG, Karvouni E, Ioannidis JP. Meta-analysis comparing drug-eluting stents with bare metal stents. Am J Cardiol 2005;95:640-3.
35. Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials 2005;2:209-17.
36. Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 2002;25:76-97.
37. Clarke MJ, Stewart LA. Meta-analyses using individual patient data. J Eval Clin Pract 1997;3:207-12.
38. Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993;341:418-22.
39. Vale CL, Tierney JF, Stewart LA. Effects of adjusting for censoring on metaanalyses of time-to-event outcomes. Int J Epidemiol 2002;31:107-11.
40. Shuchman M. Trading restenosis for thrombosis? New questions about drug-eluting stents. N Engl J Med 2006;355:1949-52.
41. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus baremetal stents. J Am Coll Cardiol 2006;48:2584-91.
42. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-68.
43. Stone GW. Perspectives on drug-eluting stent safety and efficacy with regulatory recommendations. Presented at the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee, Washington, DC, December 7-8, 2006. (Accessed February 9, 2007, at http://www.fda.gov/ohrms/dockets/ac/06/ slides/2006-4253oph1_04_Stone.pdf.)
44. Carrozza JP Jr, Kuntz RE, Levine MJ, et al. Angiographic and clinical outcome of intracoronary stenting: immediate and long-term results from a large single-center experience. J Am Coll Cardiol 1992;20:328-37.
45. Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32:1866-73.